Found: 223
Select item for more details and to access through your institution.
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
- Published in:
- 2019
- By:
- Publication type:
- journal article
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.
- Published in:
- Nephrology Dialysis Transplantation, 2024, v. 39, n. 9, p. 1504, doi. 10.1093/ndt/gfae032
- By:
- Publication type:
- Article
Ketones: the double-edged sword of SGLT2 inhibitors?
- Published in:
- Diabetologia, 2023, v. 66, n. 1, p. 23, doi. 10.1007/s00125-022-05815-1
- By:
- Publication type:
- Article
Diabetes prevention and cardiovascular complications.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
- Published in:
- Diabetologia, 2018, v. 61, n. 10, p. 2118, doi. 10.1007/s00125-018-4663-6
- By:
- Publication type:
- Article
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
- Published in:
- Diabetologia, 2018, v. 61, n. 8, p. 1712, doi. 10.1007/s00125-018-4644-9
- By:
- Publication type:
- Article
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
- Published in:
- Diabetologia, 2018, v. 61, n. 7, p. 1522, doi. 10.1007/s00125-018-4630-2
- By:
- Publication type:
- Article
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. 2888, doi. 10.1111/dom.15183
- By:
- Publication type:
- Article
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1932, doi. 10.1111/dom.15058
- By:
- Publication type:
- Article
Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 844, doi. 10.1111/dom.14933
- By:
- Publication type:
- Article
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2071, doi. 10.1111/dom.14805
- By:
- Publication type:
- Article
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1150, doi. 10.1111/dom.14687
- By:
- Publication type:
- Article
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1061, doi. 10.1111/dom.14670
- By:
- Publication type:
- Article
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 135, doi. 10.1111/dom.14559
- By:
- Publication type:
- Article
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2775, doi. 10.1111/dom.14535
- By:
- Publication type:
- Article
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1426, doi. 10.1111/dom.14352
- By:
- Publication type:
- Article
Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 5, p. 1173, doi. 10.1111/dom.14326
- By:
- Publication type:
- Article
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 425, doi. 10.1111/dom.14234
- By:
- Publication type:
- Article
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2335, doi. 10.1111/dom.14158
- By:
- Publication type:
- Article
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1141, doi. 10.1111/dom.14015
- By:
- Publication type:
- Article
Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1207, doi. 10.1111/dom.13991
- By:
- Publication type:
- Article
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 631, doi. 10.1111/dom.13938
- By:
- Publication type:
- Article
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1073, doi. 10.1111/dom.13645
- By:
- Publication type:
- Article
Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1121, doi. 10.1111/dom.13625
- By:
- Publication type:
- Article
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 720, doi. 10.1111/dom.13579
- By:
- Publication type:
- Article
Impact of treatment with pioglitazone on stroke outcomes: A real‐world database analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 9, p. 2140, doi. 10.1111/dom.13344
- By:
- Publication type:
- Article
Mysterious Hyperglycemia: Disease Versus Device.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
Speaking to Patients About Diabetes Risk: Is Terminology Important?
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Speaking to Patients About Diabetes Risk: Is Terminology Important?
- Published in:
- Clinical Diabetes, 2014, v. 32, n. 2, p. 90, doi. 10.2337/diaclin.32.2.90
- By:
- Publication type:
- Article
Oral Agents for Type 2 Diabetes: An Update.
- Published in:
- Clinical Diabetes, 2005, v. 23, n. 2, p. 64, doi. 10.2337/diaclin.23.2.64
- By:
- Publication type:
- Article
Applying the Lessons of the DPP to Clinical Practice.
- Published in:
- Clinical Diabetes, 2003, v. 21, n. 2, p. 91, doi. 10.2337/diaclin.21.2.91
- By:
- Publication type:
- Article
Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure.
- Published in:
- JAMA: Journal of the American Medical Association, 2003, v. 290, n. 1, p. 81, doi. 10.1001/jama.290.1.81
- By:
- Publication type:
- Article
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients with Type 2 Diabetes.
- Published in:
- Diabetes, 2002, v. 51, n. 3, p. 799, doi. 10.2337/diabetes.51.3.797
- By:
- Publication type:
- Article
Mechanism by which metformin reduces glucose production in type 2 diabetes.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial.
- Published in:
- Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02328-6
- By:
- Publication type:
- Article
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study.
- Published in:
- Annals of the American Thoracic Society, 2021, v. 18, n. 12, p. 2067, doi. 10.1513/AnnalsATS.202012-1556OC
- By:
- Publication type:
- Article
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Metformin in Patients With Type 2 Diabetes and Kidney Disease.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 312, n. 24, p. 2668, doi. 10.1001/jama.2014.15298
- By:
- Publication type:
- Article
Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Relationship Between Spontaneous and latrogenic Hypoglycemia and Mortality in Patients Hospitalized With Acute Myocardial Infarction.
- Published in:
- JAMA: Journal of the American Medical Association, 2009, v. 301, n. 15, p. 1556, doi. 10.1001/jama.2009.496
- By:
- Publication type:
- Article
Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes.
- Published in:
- JAMA: Journal of the American Medical Association, 2009, v. 301, n. 15, p. 1547, doi. 10.1001/jama.2009.476
- By:
- Publication type:
- Article
Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease.
- Published in:
- International Journal of Stroke, 2019, v. 14, n. 6, p. 639, doi. 10.1177/1747493018816425
- By:
- Publication type:
- Article
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-319-OR
- By:
- Publication type:
- Article
873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-873-P
- By:
- Publication type:
- Article
790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-790-P
- By:
- Publication type:
- Article
132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-132-LB
- By:
- Publication type:
- Article
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-131-LB
- By:
- Publication type:
- Article
927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-927-P
- By:
- Publication type:
- Article